To the Editor On behalf of our coauthors, we write to report errors that occurred in our article, “Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness: A Randomized Clinical Trial,”1 that was published online on March 23, 2015, and in the May 2015 issue of JAMA Internal Medicine. We believe that this represents a “pervasive error”2 warranting this letter of explanation and a Correction. The overall impact of the errors is minor and once corrected the conclusions of the study remain unchanged.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kutner JS, Abernethy AP. Coding Error Resulting in Change in Secondary Outcome Scores in Trial of Safety and Benefit of Discontinuing Statin Therapy Among Terminally Ill Patients. JAMA Intern Med. 2019;179(1):126. doi:10.1001/jamainternmed.2018.7162
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: